ARTICLE | Clinical News
Tarceva erlotinib: Additional Phase III data
July 18, 2005 7:00 AM UTC
Additional data from a subset analysis of the double-blind, placebo-controlled, international Phase III BR.21 trial in 731 patients showed that Tarceva led to a greater survival benefit in patients wi...